[{"id":"55c21f83-a0e4-4e9b-947b-7ac8365bc89c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787535","created_at":"2023-03-28T14:05:07.469Z","updated_at":"2024-07-02T16:35:21.209Z","phase":"Phase 1","brief_title":"HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT05787535","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-02"},{"id":"ef8056a0-9ebe-4f7d-a6ed-854f7c1cbfe5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952947","created_at":"2023-07-20T14:08:58.725Z","updated_at":"2024-07-02T16:35:21.083Z","phase":"Phase 1","brief_title":"HRYZ-T101 Injection for HPV18 Positive Solid Tumor","source_id_and_acronym":"NCT05952947","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-02-02"}]